Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @OncLive
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @OncLive
-
Prikvačeni tweet
We spoke with
@LeciaSequist and@ZPiotrowskaMD of@MGHCancerCenter about remaining questions in immunotherapy and targeted therapy for advanced#NSCLC in this week's#OncLiveOnAir#lcsm#lcam http://ow.ly/GAFV50y8dZQ pic.twitter.com/oipwfhOkJE
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Nivolumab plus ipilimumab in the frontline setting for patients with advanced
#NSCLC led to an improvement in overall survival over chemotherapy, regardless of PD-L1 expression#lcsm#lcam@DrRoyHerbstYale@YaleCancerhttp://ow.ly/QmWV50ydGTcHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Over the past few years, substantial progress has been made in the understanding and development of systemic therapies in
#cancer care; however, the impact of these advancements on surgical care has only come to light recentlyhttp://ow.ly/Nnnb50ydGPiHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The emergence of CDK4/6 inhibitors has impacted treatment decisions for patients with HR+, HER2-
#breastcancer, allowing for more options and leading to more investigational efforts#bcsm@MAccordino@columbiacancerhttp://ow.ly/JwW150ydGLtHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Data suggest that baseline T-cell clonality and exhaustion markers have significant translational relevance and can serve as prognostic factors of response to pembrolizumab as maintenance therapy in metastatic
#breastcancer#bcsm@MDAndersonNewshttp://ow.ly/3veC50ydGESHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Risk status should be used to help decide whether premenopausal women with early-stage HR+
#breastcancer need more intensive therapy with an aromatase inhibitor#bcsm@DrDawnHershman@columbiacancerhttp://ow.ly/DdGm50ydGzIHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@EConnollyRadOnc of@columbiacancer reflects on novel radiation techniques, as well as ongoing research and challenges with radiation therapy in#breastcancer#bcsmhttp://ow.ly/1ltY50yeLn6Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antonio González-Martín, MD, of Clinica Universidad de Navarra discusses the design and findings of the PRIMA trial in advanced
#ovariancancer#ovcahttp://ow.ly/geq850yeLl0Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Katherine D. Crew, MD, of
@nyphospital and@columbiacancer discusses the updated results of the KATHERINE trial, as well as other data regarding the adjuvant treatment paradigm in early-stage#HER2+#breastcancerhttp://ow.ly/smTA50yeLcBHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@ThomasPolascik of@DukeCancer discusses the growing relevance of genetic testing for men with#prostatecancer and those at a high risk of developing the disease#pcsmhttp://ow.ly/cYPF50yeL6SHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@breastoncdoc of@UPMCHillmanCC discusses the emergence of#biosimilars in oncology and how he anticipates they will change the paradigmhttp://ow.ly/CY0l50yeL2mHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Although the Centers for Medicare & Medicaid Services has leapt forward with a vision for the next-generation model of care Oncology Care First, many stakeholders feel that the OCM is more than enough to think about right now
#cancer#oncologyhttp://ow.ly/X3mJ50yeKWLHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Although the human epidermal growth factor receptor family of receptor tyrosine kinases plays a central role in the development of human cancers, efforts to target its activity therapeutically have focused thus far on 2 of its now famous members
#cancerhttp://ow.ly/xkj950yeKQpHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Research Efforts Continue With Radiation Therapy in
#BreastCancer#bcsm@EConnollyRadOnc@columbiacancerhttp://ow.ly/c1vO50yeKrzHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We spoke with experts from
@TexasOncology to gather updates on#precisionmedicine initiatives in#lungcancer and#pancreaticcancer, including biomarkers and molecular testing#lcsm#pancsm#OncLiveOnAir http://ow.ly/qD1I50yeJMy pic.twitter.com/6W1GA17O1H
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Niraparib Emerges as a Frontline Maintenance Standard in Advanced
#OvarianCancer#ovcahttp://ow.ly/vpfk50yeDoSHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Updated Data Refine Adjuvant Paradigm in
#HER2+ Early#BreastCancer#bcsm@nyphospital@columbiacancerhttp://ow.ly/V03J50yewaJHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
OncLive.com proslijedio/la je Tweet
The
@OncLive State of the Science summit “The Treatment of#LungCancer” will be held on 2/11 from 5-9pm at the Sofitel Hotel near#CedarsSinai Medical Center. Presenters include researchers from#CedarsSinaiCancer and other institutions.@KarenReckampMD https://www.onclive.com/meetings/soss pic.twitter.com/uC08hkIG3y
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
OncLive.com proslijedio/la je Tweet
Talking Tumors: Contemplating Clinical Conundrums in Lung Cancer.
@OncLive podcast features#MassGeneral physicians Lecia Sequist, MD, and Zofia Piotrowska, MD.@LeciaSequist http://ow.ly/NVwO50yd7y1Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Education, Collaboration Key to Increasing Genetic Screening in
#ProstateCancer#pcsm@ThomasPolascik@DukeCancerhttp://ow.ly/9E3o50yerVNHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#Biosimilars Enter US Market, Poised to Impact#Cancer Treatment@breastoncdoc@UPMCHillmanCChttp://ow.ly/Sm9R50yepLJHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.